Use of research biopsies in clinical trials: are risks and benefits adequately discussed? - Wikidata - awgldk - TriplyDB

Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

http://www.wikidata.org/entity/Q41264496

about

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer Serum HER2 Is a Potential Surrogate for Tissue HER2 Status in Gastric Cancer: A Systematic Review and Meta-Analysis Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity Liquid biopsies: genotyping circulating tumor DNA High-Density Dielectrophoretic Microwell Array for Detection, Capture, and Single-Cell Analysis of Rare Tumor Cells in Peripheral Blood Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer Ethical Issues in the Management of Renal Cell Carcinoma.Changes of Microrna Levels in Plasma of Patients with Rectal Cancer during Chemoradiotherapy.Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217)Research biopsies in the context of early phase oncology studies: clinical and ethical considerations.Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer.Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer.Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients Prognostic Impact of Modulators of G proteins in Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer.An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment.Reporting practices of pharmacodynamic studies involving invasive research procedures in cancer trials.Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.Prospective clinical experience with research biopsies in breast cancer patients.Image-Guided Biopsy in the Era of Personalized Cancer Care: Proceedings from the Society of Interventional Radiology Research Consensus Panel.Neoadjuvant Therapy in Rectal Cancer - Biobanking of Preoperative Tumor Biopsies.Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA.Biopsies: next-generation biospecimens for tailoring therapy.Cell-free DNA as a novel marker in cancer therapy.Liquid biopsies in lung cancer-time to implement research technologies in routine care?Clinical Applications of Liquid Biopsies in Gastrointestinal Oncology.PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation.Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression.Role of circulating free DNA in colorectal cancer.Liquid biopsies come of age: towards implementation of circulating tumour DNA.Efficacy of a Self-expanding Tract Sealant Device in the Reduction of Pneumothorax and Chest Tube Placement Rates After Percutaneous Lung Biopsy: A Matched Controlled Study Using Propensity Score Analysis.

P2860

Q26775376-78D35F01-E806-4225-B19A-4BD1E77A5064 Q26796280-ED9C5487-1271-45C5-A1CC-911BEC362EC9 Q26801357-0B074F55-1749-4B33-963F-3B978486E02E Q26992272-FAC15793-38A2-49DA-ABE5-EFBD455173DC Q27010159-42D1F23B-45C0-413B-9432-70D37580A158 Q27304104-F5A6641B-B9F4-4A13-8357-7FA240DF0133 Q28073765-FF651EA8-0065-4A92-A303-7F0B0DB8C833 Q30724257-6A177EB5-65F6-4F9C-B004-47ADE0172CA5 Q33838484-5C123261-4E85-4E5E-8860-A10F625FDAAC Q33889715-9DDCCC22-7812-4C02-A87E-0666882019CE Q33992410-07EECD49-9FBB-41F1-86AC-C7F62472F8FB Q35569312-31A27DEC-9F27-4B8D-96B8-334B4D47C315 Q35810461-D216EE3B-E12A-403F-B265-94D08CB25B32 Q36064901-EDAD8544-238E-4AFC-ACAF-62459BE1DEB8 Q36376138-22D50B2C-570F-4847-836B-0B4B4F8D6D4B Q36545624-C58DBCA4-189F-4734-9873-CEC73D2D733E Q36621729-2A91008D-50D9-41E8-B1D4-8DAADB5088EF Q36779225-79AE3D26-2560-47F3-B2C1-C5ADCB3325B9 Q36844366-8BCAAE26-2BC9-416B-A651-C44040C2B027 Q37111197-E1D2AC37-A38B-4F77-8D6B-CDFD3DED36C9 Q37249366-F869EA93-6E92-49BB-9072-E615979D0DE4 Q37301389-B33F71AD-79A9-49E2-8A78-80840BC25F49 Q37324763-5FDA84CE-7F39-4B55-8DF8-43EFD6B24B21 Q37345859-64BED8AE-6731-4556-B1F7-A7C209535359 Q37362696-3A3DE13D-6681-424B-A26D-C6A41F6287F8 Q37536958-6975C9ED-21F6-467E-942D-24DB6890D3CF Q37662237-FBF10BA1-04FA-4B68-BE4C-C935BDD962EB Q37662351-911D0D4D-130A-480F-B7B6-A15A28D1E726 Q37684125-324B2248-5A59-4D85-B37C-AAF5D06E005F Q37690677-D9CB616E-AC9B-4CCC-8773-6303B7DE74EC Q37723666-87ACF6B5-0334-49CD-89F6-3E4C07E6873A Q38116896-EE8CCAC8-FA29-4423-B33C-2F7E4905B11D Q38547170-E46BB12D-5422-43A1-9C14-FDADA1F8ED00 Q38649535-434D14F6-85CA-4314-B184-99A41F3E2612 Q38800475-0BFE4CD8-61B6-4EF0-9B1E-E9E130DCEEF3 Q38838347-BA959F16-2CAA-4D3A-9289-B28969B5EAEF Q39002233-2DB69931-23CF-4EA7-9472-93BE5A2A2212 Q39051652-531BEA94-7DD3-4200-9D31-84EDC469BD46 Q39149201-7DBF3B28-9753-4F50-AC3C-19DE322578AB Q39202843-1AC1AECB-FF3B-400A-BE5E-4A9B9445BCBE

P2860

Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

http://www.wikidata.org/entity/Q41264496

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

@en

type

label

Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

@en

prefLabel

Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

@en

P1433

Q41264496-F0F87FDB-4C5B-46C6-9118-AED01A50255E

P1476

Q41264496-3D3450EC-0F59-4452-B114-8160BB6CDCB9

P2093

Q41264496-476A1858-F15C-4129-83C9-8B2DBF07A5C6

Q41264496-51520833-F022-49B8-BE6A-EF80C41F7116

Q41264496-64058AD8-FECF-4441-804D-B006083EB88C

Q41264496-878C390A-85A9-4C3A-9FCF-D142C9FFFA4E

Q41264496-CA937310-0E8C-4FD3-983E-973483B0F991

Q41264496-D4C5A08A-A560-4E78-8942-BA8316B2C9E7

Q41264496-D6070728-E2D0-469E-A10E-8DA5FCA21561

Q41264496-EF678BA0-EDF5-45A6-B7FD-19DBEE09CDC7

P2860

Q41264496-0F108F6A-DE3D-4295-BF3F-86486731E64B

Q41264496-0FD5D0EA-52C8-4B81-93A9-FD31C7A8B79F

Q41264496-13CF9596-960D-420D-B4AD-F2973A2BA13E

Q41264496-1DCA41C8-2E85-4D75-BADD-C24C9C89760E

Q41264496-35DE8855-4F76-47C2-A4A8-FE3105803CB1

Q41264496-385ECF82-8BB6-4AD5-809B-BFD24A5D18CA

Q41264496-448CF725-41D6-4670-A412-1B88C074A080

Q41264496-54DDD6D9-5D42-4366-971D-D6EA48A9E94C

Q41264496-56E4E698-DB40-421E-8702-AB8EF4C32C71

Q41264496-7378DC81-2DD1-4401-A879-DD6D10225DBB

P304

Q41264496-D5280B73-3875-417F-901A-B99399BA183B

P31

Q41264496-0029CA34-CED5-405D-93D4-352ED60BF5FA

P356

Q41264496-FD8390D3-C380-4C05-9B3C-CD34EB9437B2

P407

Q41264496-7164A78A-5C5A-40F5-BA7B-5EB5AB9F845F

P433

Q41264496-DC23C5AF-6074-472F-A1E8-05686294E09D

P478

Q41264496-753491AC-008B-47AE-B0F0-C89285AD3CD4

P577

Q41264496-61188DBF-0AEA-4ADB-9A3C-7F35181252D2

P5875

Q41264496-DB0B105E-EB84-44B0-BE7E-F4403CAA018C

P698

Q41264496-B4C2690A-6FC1-4DC4-B456-C771F19649C0

P932

Q41264496-3D548A96-73A3-4C1E-9D73-4E1840FBEC80

P356

JCO.2012.43.1718

P1433

Journal of Clinical Oncology

P1476

Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

@en

P2093

Alda L Tam

http://www.w3.org/2001/XMLSchema#string

James C Yao

http://www.w3.org/2001/XMLSchema#string

James L Abbruzzese

http://www.w3.org/2001/XMLSchema#string

Janhavi Modak

http://www.w3.org/2001/XMLSchema#string

Marshall E Hicks

http://www.w3.org/2001/XMLSchema#string

Michael J Overman

http://www.w3.org/2001/XMLSchema#string

Ravi Murthy

http://www.w3.org/2001/XMLSchema#string

Scott Kopetz

http://www.w3.org/2001/XMLSchema#string

P2860

What makes clinical research ethical?

Quality of informed consent in cancer clinical trials: a cross-sectional survey.

Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons.

Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience.

Tissue collection for correlative studies in childhood cancer clinical trials: ethical considerations and special imperatives.

Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents.

The ethical use of mandatory research biopsies

Performing nondiagnostic research biopsies in irradiated tissue: a review of scientific, clinical, and ethical considerations

Trends in the use and role of biomarkers in phase I oncology trials.

Bench to bedside: mapping the moral terrain of clinical research.

P304

17-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2012.43.1718

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232920929

http://www.w3.org/2001/XMLSchema#string

P698

23129736

http://www.w3.org/2001/XMLSchema#string

P932

5545102

http://www.w3.org/2001/XMLSchema#string